Radar · Life Sciences in London
Best Life Sciences Companies in London, United Kingdom
The 632 best Life Sciences companies in London, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Isomorphic Labs.
By Riya SenguptaFinancials
632companies tracked
$12.1Bdisclosed funding
1unicorns
295have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × LONDON
Our analysis of 62 Life Sciences companies
$9.8b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2026.
62companies analysed
75%cloud-native stacks
2026funding peak (by rounds)
2unicorns
2016median founding year
517kcombined LinkedIn audience
41%of audience held by top 3
4companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in London
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Isomorphic Labs Digital platform focused on revolutionizing drug discovery using AI 60Funding top 12%AI top 20%Innovation top 30%Patents top 33% All 11 signals ▾Fundingtop 12% AItop 20% Innovationtop 30% Patentstop 33% Moattop 39% Talentbottom 49% Growthbottom 47% Techbottom 46% Globalbottom 37% Marketbottom 36% Newsbottom 25% Funding: Raised $2.7B across 2 rounds · 2 rounds over 1 yrs (2.0/yr) AI: Classified as an AI company rank vs industry peers · Fliar Intelligence Index 60/100 | $2.7B | 1 mo ago | — | Demis Hassabis Founder & CEO | WebflowThree.jsGSAP+14 | 19 patents AI-driven drug discovery: protein‑ligand modeling, molecule property prediction, synthesis feasibility. | — |
| 2 | Orchard Therapeutics Developer of gene therapies for treating rare diseases | $440M | 39 mo ago | 117 117 → 247 (+111%) | Bobby Gaspar CEO | WordPressDrupalMySQL+27 | 38 patents Gene‑editing therapies for autoimmune and hereditary angioedema disorders | — |
| 3 | Verdiva Bio Developer of oral and injectable peptide therapies for metabolic diseases 50Funding top 21%Moat top 40%Market bottom 49%Talent bottom 49% All 5 signals ▾Fundingtop 21% Moattop 40% Marketbottom 49% Talentbottom 49% Globalbottom 45% Funding: Raised $411M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Moat: Soonicorn · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 50/100 | $411M | 17 mo ago | — | Khurem Farooq Co-Founder & CEO | — | — | — |
| 4 | Avacta Developer of drug delivery technology using tumor activated peptide linkers 24Funding top 21%News top 35%Moat top 38%Talent bottom 49% All 11 signals ▾Fundingtop 21% Newstop 35% Moattop 38% Talentbottom 49% Techbottom 47% Patentsbottom 42% Growthbottom 41% Globalbottom 41% Marketbottom 40% Innovationbottom 36% Fin. healthbottom 20% Funding: Raised $222M across 12 rounds · 12 rounds over 15 yrs (0.8/yr) News: 7 BI events in 12 mo (of 34 tracked, 8 types) · -46% YoY rank vs industry peers · Fliar Intelligence Index 24/100 | $222M | 7 mo ago | 90 90 → 47 (-48%) | Christina Coughlin CEO | WordPressApple iCloud MailMicrosoft 365+17 | 17 patents Microfluidic reagent dispensing with optical/Raman detection for nucleic acid analysis | — |
| 5 | Pheon Therapeutics Developer of antibody drug conjugates for treating solid tumor cancers | $188M | 24 mo ago | 8 | Bertrand Damour CEO | — | 37 patents Targeted antibody‑drug conjugates and novel cytotoxic small‑molecule therapeutics. | 1 job opening |
| 6 | Autolus Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases | $181M | 28 mo ago | 51 | Martin Pule Founder | Apple iCloud MailMicrosoft 365GSAP+17 | 648 patents Patents concentrated in chemistry & materials | 1 award |
| 7 | Purespring Therapeutics Developer of therapeutics for chronic renal diseases | $164M | 20 mo ago | 50 | Moin Saleem Co-Founder | WordPressMySQLPHP+23 | 28 patents Patents concentrated in chemistry & materials | 1 award |
| 8 | Genomics Provider of genomic risk assessment and prevention platform 64Patents top 19%Innovation top 24%Funding top 24%Talent top 28% All 9 signals ▾Patentstop 19% Innovationtop 24% Fundingtop 24% Talenttop 28% Moattop 32% Growthtop 45% Globaltop 46% Techtop 50% Marketbottom 40% Patents: 48 patents matched (strict assignee match) · 33 filings since 2022 vs 13 in 2017-21 Innovation: 48 patents (top 22% of patent-holders) · 33 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $161M | 29 mo ago | — | Rebecca H Founder & Principal | HubSpot CMS HubApple iCloud Mailcore-js+14 | 48 patents Software platforms for computational analysis of genomic sequencing data | — |
| 9 | Elvie Internet first brand offering wearable breast pumps 76Funding top 28%Tech top 28%Fin. health top 28%Moat top 28% All 11 signals ▾Fundingtop 28% Techtop 28% Fin. healthtop 28% Moattop 28% Producttop 31% Customerstop 34% Talenttop 38% Markettop 39% Growthtop 43% Globalbottom 45% Newsbottom 24% Funding: Raised $158M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) Tech: 59 technologies across 4/8 capability areas · Cloud: Amazon Web Services, Azure rank vs industry peers · Fliar Intelligence Index 76/100 | $158M | 25 mo ago | 102 102 → 116 (+14%) | Michaela Tod Chief Executive Officer | Cart FunctionalityBigCommerceApple iCloud Mail+36 | — | 2 launchs · 1 award |
| 10 | Myricx Bio Developer of antibody drug conjugates for the treatment of cancer | $121M | 23 mo ago | 6 | Robin Carr CEO | WordPressMySQLPHP+10 | — | — |
| 11 | Automata Developer of modular lab automation platforms for biological research workflows 64Funding top 25%Product top 25%Tech top 27%Moat top 31% All 11 signals ▾Fundingtop 25% Producttop 25% Techtop 27% Moattop 31% Innovationtop 32% Fin. healthtop 33% Newstop 43% Growthtop 48% Talentbottom 49% Marketbottom 44% Globalbottom 39% Funding: Raised $107M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) Product: 7 distinct product lines · Company stage: Series C rank vs industry peers · Fliar Intelligence Index 64/100 | $107M | 4 mo ago | 40 | Mostafa ElSayed Co-Founder & CEO | WordPress Block EditorWordPressApple iCloud Mail+33 | — | 1 partnership |
| 12 | Vicebio Developer of vaccines to treat viral infectious diseases 35Growth top 15%Funding top 26%News top 26%Moat top 47% All 9 signals ▾Growthtop 15% Fundingtop 26% Newstop 26% Moattop 47% Talentbottom 49% Globalbottom 37% Patentsbottom 35% Marketbottom 25% Innovationbottom 22% Growth: Fresh capital in last 24 mo Funding: Raised $100M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $100M | 20 mo ago | 4 | Emmanuel Hanon CEO | — | 2 patents Recombinant chimeric fusion protein vaccines for hMPV and RSV respiratory viruses | — |
| 13 | Amber Therapeutics Developer of bioelectrical therapies for functional disorders of the peripheral nervous system | $100M | 24 mo ago | 9 | Tim Denison Co-Founder | Webflowcore-jsjQuery+10 | 20 patents Neurostimulation devices for urinary incontinence and sexual dysfunction management | 3 job openings |
| 14 | Basecamp Research Biotechnology company using AI to explore undiscovered biology for applications in pharma, food, and industry 48AI top 20%Funding top 25%Talent top 38%Moat bottom 48% All 10 signals ▾AItop 20% Fundingtop 25% Talenttop 38% Moatbottom 48% Growthbottom 47% Techbottom 47% Partnersbottom 43% Newsbottom 41% Globalbottom 39% Marketbottom 27% AI: Classified as an AI company Funding: Raised $85.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $85M | 21 mo ago | 10 | Oliver Vince Co-Founder | WordPressApple iCloud MailMySQL+21 | — | 1 launch |
| 15 | Cytospire Therapeutics Provider of immune cell engagers for treating cancer 53Funding top 24%Global top 45%Talent bottom 49% All 3 signals ▾Fundingtop 24% Globaltop 45% Talentbottom 49% Funding: Raised $83.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Global: Investors from 4 countries beyond United Kingdom rank vs industry peers · Fliar Intelligence Index 53/100 | $83M | 1 mo ago | — | Natalie Mount CEO | — | — | 1 award |
| 16 | Alchemab Developer of antibody therapeutics for treating oncology and neurodegenerative conditions 45Funding top 28%Talent top 28%Moat top 31%Growth top 35% All 7 signals ▾Fundingtop 28% Talenttop 28% Moattop 31% Growthtop 35% Globalbottom 37% Marketbottom 34% Techbottom 33% Funding: Raised $82.7M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $83M | 9 mo ago | 8 | Jane Osbourn Co-Founder & CEO | WordPress Block EditorWordPressMySQL+14 | — | — |
| 17 | Charm Therapeutics Developer of menin inhibitors designed for acute myeloid leukemia treatment 50Funding top 24%News top 29%Moat top 31%Growth top 32% All 8 signals ▾Fundingtop 24% Newstop 29% Moattop 31% Growthtop 32% Talenttop 33% Techbottom 49% Globalbottom 37% Marketbottom 29% Funding: Raised $70.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) News: 4 BI events in 12 mo (of 8 tracked, 3 types) · +300% YoY rank vs industry peers · Fliar Intelligence Index 50/100 | $70M | 9 mo ago | 16 16 → 32 (+100%) | Laksh Aithani Co-Founder & CEO | WordPressMySQLPHP+22 | — | — |
| 18 | Allplants Online retailer of prepared, plant-based meals delivered directly to consumers 74Growth top 13%Product top 26%Tech top 30%Moat top 31% All 10 signals ▾Growthtop 13% Producttop 26% Techtop 30% Moattop 31% Fundingtop 32% Innovationtop 33% Markettop 49% Fin. healthbottom 46% Globalbottom 37% Newsbottom 21% Growth: Headcount 48 → 99 (+106%) across vintages · Fresh capital in last 24 mo Product: 9 distinct product lines · Company stage: Acquired rank vs industry peers · Fliar Intelligence Index 74/100 | $70M | 23 mo ago | 99 | — | Cart FunctionalityShopifyTailwind CSS+19 | — | — |
| 19 | Relation AI-based drug development tools for researchers 55Funding top 25%Talent top 28%AI top 30%Growth top 35% All 8 signals ▾Fundingtop 25% Talenttop 28% AItop 30% Growthtop 35% Moattop 36% Techbottom 43% Globalbottom 37% Marketbottom 27% Funding: Raised $65.3M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 55/100 | $65M | 6 mo ago | 12 | Jake Taylor-King Co-Founder & Chief Innovation Officer | Craft CMSApple iCloud MailGoogle Workspace+11 | — | 1 partnership · 1 award |
| 20 | Engitix Developer of technology for in vitro drug discovery 42Growth top 35%Talent top 38%Funding top 39%News top 43% All 10 signals ▾Growthtop 35% Talenttop 38% Fundingtop 39% Newstop 43% Patentstop 44% Moattop 47% Techtop 50% Innovationbottom 43% Globalbottom 42% Marketbottom 32% Growth: Fresh capital in last 24 mo Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $60M | 5 mo ago | 16 | Massimo Pinzani Co-Founder | WebflowApple iCloud MailGSAP+11 | 4 patents Patents concentrated in chemistry & materials | 1 partnership |
| 21 | CoMind Provider of a non-invasive brain-computer interface solution for various industries 55Growth top 11%News top 24%Funding top 29%Moat top 42% All 9 signals ▾Growthtop 11% Newstop 24% Fundingtop 29% Moattop 42% Partnerstop 45% Talentbottom 49% Marketbottom 38% Globalbottom 37% Techbottom 36% Growth: Headcount 15 → 36 (+140%) across vintages · Fresh capital in last 24 mo News: 7 BI events in 12 mo (of 7 tracked, 2 types) · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $60M | 7 mo ago | 36 36 → 81 (+125%) | James Dacombe Co-Founder & CEO | Framer SitesApple iCloud MailGoogle Workspace+8 | — | — |
| 22 | Epsilogen Developer of immunoglobulinE antibodies for the treatment of cancer | $54M | 21 mo ago | 4 | Tim Wilson CEO at Epsilogen Ltd | WordPressMySQLPHP+17 | 19 patents Engineered therapeutic antibodies, especially IgE and hybrid formats targeting HER2 low-expression cancers | — |
| 23 | Latentlabs Developer of generative AI models for programmable biology 60Funding top 25%AI top 30%Growth top 35%Moat top 40% All 8 signals ▾Fundingtop 25% AItop 30% Growthtop 35% Moattop 40% Talentbottom 49% Globalbottom 48% Techbottom 43% Marketbottom 40% Funding: Raised $50.0M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) AI: Classified as an AI company · Product described with: generative ai rank vs industry peers · Fliar Intelligence Index 60/100 | $50M | 16 mo ago | — | Simon Kohl Founder & CEO | WordPressMySQLPHP+18 | — | — |
| 24 | Portal Biotech Developer of biosensing technology that utilizes bioengineered nanopores to analyze proteins and metabolomics | $45M | 14 mo ago | — | Giovanni Maglia Co-Founder | Apple iCloud MailMicrosoft 365Ruby+14 | 13 patents Nanopore-based biomolecular sensing and protein/ analyte detection technologies. | — |
| 25 | TympaHealth Provider of an AI-based hearing health diagnosis device for medical professionals 57Growth top 28%Funding top 32%Talent top 33%Tech top 41% All 8 signals ▾Growthtop 28% Fundingtop 32% Talenttop 33% Techtop 41% AItop 45% Productbottom 48% Globalbottom 37% Marketbottom 25% Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo Funding: Raised $31.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $31M | 0 mo ago | 7 | Krishan Ramdoo Founder & CEO | WordPressApple iCloud MailMicrosoft 365+22 | — | — |
| 26 | Kesmalea Developer of protein homeostasis modulators for therapeutic applications | $30M | 21 mo ago | 5 | Harry Finch Founder Director | WordPressMySQLPHP+13 | — | — |
| 27 | Bioniq Provider of personalized nutritional supplements using patented Swiss granules | $30M | 11 mo ago | 61 | Constantin Karuzin Co-Founder & Medical Director | Webflow EcommerceWebflowBootstrap+35 | — | — |
| 28 | LIfT Biosciences Developer of neutrophil-based cell therapies for solid tumors | $20M | 10 mo ago | 8 | — | — | 69 patents Manufacturing and therapeutic use of engineered immune cells for cancer treatment | — |
| 29 | Valink Therapeutics Developer of bispecific antibody-drug conjugate therapeutics for oncology and other diseases | $20M | 7 mo ago | — | Irsyad Khairil Co-Founder & CTO | WebflowApple iCloud MailMicrosoft 365+10 | — | — |
| 30 | Techspert Leading expert network for healthcare and life sciences 60Funding top 29%Tech top 30%Growth top 32%Moat top 39% All 7 signals ▾Fundingtop 29% Techtop 30% Growthtop 32% Moattop 39% Talentbottom 49% Globalbottom 46% Marketbottom 42% Funding: Raised $18.1M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Tech: 43 technologies across 5/8 capability areas · Cloud: Amazon Cloudfront, Amazon S3 rank vs industry peers · Fliar Intelligence Index 60/100 | $18M | 3 mo ago | 53 53 → 71 (+34%) | David Holden Co-Founder & CEO | HubSpot CMS HubSalesforceBootstrap+25 | — | — |
| 31 | Endlyz Developer of small-molecule therapeutics targeting lysosomal dysfunction in neurodegenerative diseases 24Funding top 32%Tech bottom 49%Talent bottom 49%Global bottom 48% All 5 signals ▾Fundingtop 32% Techbottom 49% Talentbottom 49% Globalbottom 48% Marketbottom 25% Funding: Raised $17.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Tech: 13 technologies across 4/8 capability areas · Cloud: Vercel rank vs industry peers · Fliar Intelligence Index 24/100 | $17M | 2 mo ago | — | Joanna Wolak Co-Founder & CEO | Node.jsTailwind CSSReact+10 | — | — |
| 32 | GripAble Provider of cloud-based rehabilitation device with a companion app for the patients 53Growth top 21%Funding top 32%AI top 45%Talent bottom 49% All 8 signals ▾Growthtop 21% Fundingtop 32% AItop 45% Talentbottom 49% Productbottom 48% Techbottom 45% Globalbottom 37% Marketbottom 27% Growth: Headcount 11 → 27 (+145%) across vintages · Fresh capital in last 24 mo Funding: Raised $16.5M across 6 rounds · 6 rounds over 9 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $17M | 3 mo ago | 27 27 → 17 (-37%) | Mike Mace CTO - Cofounder | WordPressMySQLSalesforce+22 | — | — |
| 33 | Electric Twin AI-powered digital twin technology for research and clinical applications in the life sciences industry 60Growth top 15%News top 22%Funding top 33%Talent top 38% All 8 signals ▾Growthtop 15% Newstop 22% Fundingtop 33% Talenttop 38% AItop 45% Techtop 46% Globalbottom 32% Marketbottom 25% Growth: Fresh capital in last 24 mo News: 6 BI events in 12 mo (of 6 tracked, 1 types) · 6 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $14M | 9 mo ago | — | Alex Cooper Co-Founder & CEO | Framer SitesYouTubeReact+21 | — | 2 awards |
| 34 | Palarum Provider of eTextile wearable technology for patients 45Innovation top 23%Product top 36%Talent top 38%Funding top 46% All 7 signals ▾Innovationtop 23% Producttop 36% Talenttop 38% Fundingtop 46% Techtop 49% Globalbottom 37% Marketbottom 25% Innovation: 9 product lines · Deep-tech classification: Tech Hardware Product: 9 distinct product lines · Company stage: Series A rank vs industry peers · Fliar Intelligence Index 45/100 | $11M | 13 mo ago | — | Chris Baker Co-Founder & VP Of BD & Marketing | WordPressApple iCloud MailMySQL+28 | — | 1 launch |
| 35 | OKYO Pharma Developer of therapeutics for the treatment of dry eye disease and chronic pain management | $10M | 10 mo ago | 6 | Gary Jacob Chief Executive Officer | WordPressMySQLPHP+10 | — | 2 expansions |
| 36 | Echopoint Medical Developer of smart devices for monitoring coronary artery disease and microvascular dysfunction | $10M | 6 mo ago | 8 | Ioannis Papakonstantinou Co-Founder | WordPressMySQLPHP+10 | — | — |
| 37 | Poolbeg Pharma Developer of therapeutics for the treatment of infectious diseases | $9M | 12 mo ago | 7 | Carol Dalton Co-Founder | WordPress Block EditorWordPressMySQL+21 | 18 patents p38 MAPK inhibitor therapeutics for cytokine storm mitigation in influenza and cancer immunotherapy | — |
| 38 | Ignota Labs AI-driven toxicity prediction tools for early-stage drug discovery scientists | $7M | 15 mo ago | 9 | Layla Hosseini-Gerami Co-Founder | — | — | 2 partnerships · 1 award |
| 39 | DaltonTx Developer of AI-enabled platforms for drug discovery and development 35Talent top 28%Funding top 40%AI top 45%Global bottom 48% All 6 signals ▾Talenttop 28% Fundingtop 40% AItop 45% Globalbottom 48% Techbottom 36% Marketbottom 25% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $5.4M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $5M | 8 mo ago | — | Adrian Rossall Co-Founder & CTO | Framer SitesReactLenis+7 | — | — |
| 40 | BoobyBiome Developer of research-backed microbiome solutions for infant health and well-being | $5M | 9 mo ago | 4 | Tara O'Driscoll Co-Founder & CEO | WixSentryBootstrap+11 | 2 patents Anaerobic microbial preservation packaging and storage systems | — |
| 41 | Little Journey Provider of digital health solutions for pediatric healthcare 29Growth top 35%Funding top 36%Talent top 38%Product top 47% All 8 signals ▾Growthtop 35% Fundingtop 36% Talenttop 38% Producttop 47% Globalbottom 39% Techbottom 34% Marketbottom 19% Newsbottom 18% Growth: Fresh capital in last 24 mo Funding: Raised $5.2M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 29/100 | $5M | 11 mo ago | 1 | Chris Evans Co-Founder & CEO | HubSpot CMS HubApple iCloud MailMicrosoft 365+9 | — | 1 job opening · 1 award |
| 42 | TernaryTx Developer of computational platform for molecular glue discovery and design 24Talent top 38%Funding top 42%AI top 45%Global bottom 48% All 6 signals ▾Talenttop 38% Fundingtop 42% AItop 45% Globalbottom 48% Marketbottom 25% Techbottom 22% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $4.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 24/100 | $5M | 3 mo ago | — | Chris Tame Co-Founder & CEO | Tiiny HostAmazon Web ServicesPlausible+4 | — | 1 internship |
| 43 | Entelo Bio Developer of single-cell isoform sequencing platform for disease research 42Talent top 38%Funding top 47%Global bottom 48% All 3 signals ▾Talenttop 38% Fundingtop 47% Globalbottom 48% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $4.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $4M | 1 mo ago | — | Adam Cribbs Co-Founder & CTO | — | — | 1 launch · 1 partnership · 1 award |
| 44 | Solvonis Therapeutics Developer of novel therapeutics for addiction and mental health disorders | $3M | 8 mo ago | — | Anthony Tennyson Co-Founder & Chief Executive Officer | Framer SitesReactPriority Hints+6 | — | — |
| 45 | Gibran Platform offering AI research and development solutions 45AI top 20%Talent top 28%Growth top 35%Funding bottom 48% All 7 signals ▾AItop 20% Talenttop 28% Growthtop 35% Fundingbottom 48% Globalbottom 45% Techbottom 29% Marketbottom 25% AI: Classified as an AI company Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $3M | 9 mo ago | — | Govind Balakrishnan Co-Founder | Google Font APIGoDaddyCloudflare Bot Management+2 | — | — |
| 46 | Samphire Neuroscience Developer of neuroscientific tools for PMS and period pain relief. | $2M | 12 mo ago | 2 | Emile Radyte Co-Founder & CEO | Cart FunctionalityShopifyApple iCloud Mail+29 | 3 patents Patents concentrated in health & consumer products | — |
| 47 | Sable Bio AI-powered platform for drug safety prediction within the pharmaceutical industry 32Talent top 38%Funding top 44%AI top 45%Moat top 48% All 7 signals ▾Talenttop 38% Fundingtop 44% AItop 45% Moattop 48% Techbottom 45% Globalbottom 32% Marketbottom 28% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $1.9M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $2M | 9 mo ago | — | Josh Almond-Thynne Co-Founder | Framer SitesReactAmazon Web Services+10 | — | 1 partnership |
| 48 | PolyModels Hub Provider of a platform to accelerate drug development 29Talent top 28%News top 32%Funding top 43%Moat top 48% All 7 signals ▾Talenttop 28% Newstop 32% Fundingtop 43% Moattop 48% Techbottom 48% Globalbottom 37% Marketbottom 28% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated News: 3 BI events in 12 mo (of 4 tracked, 2 types) · +200% YoY rank vs industry peers · Fliar Intelligence Index 29/100 | $1M | 6 mo ago | — | Antonio Yankey Co-Founder | ContentfulApple iCloud MailGoogle Workspace+14 | — | 1 launch |
| 49 | Atocap Manufacturer of microencapsulated drugs | $1M | 3 mo ago | 5 | Heather King CEO | — | — | — |
| 50 | Klaris Provider of AI-powered compliance solutions for medical device manufacturers 27Talent top 38%AI top 45%Funding bottom 47%Global bottom 45% All 6 signals ▾Talenttop 38% AItop 45% Fundingbottom 47% Globalbottom 45% Techbottom 39% Marketbottom 25% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated AI: Product described with: ai-powered rank vs industry peers · Fliar Intelligence Index 27/100 | $1M | 3 mo ago | — | Mihai Sorin Co-Founder & CTO | Apple iCloud MailGoogle WorkspaceGoogle Cloud+7 | — | — |
Top 12 Life Sciences companies in London
#1
Series B · London, England · founded 2021$2.7Braised▾
Series B · London, England · founded 2021
Digital platform focused on revolutionizing drug discovery using AI. The company's computational tools analyze complex biological phenomena to assist in the design of molecules. The technology predicts how potential therapeutic compounds perform to facilitate the development of treatments for various diseases.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 12%AI
top 20%Innovation
top 30%Patents
top 33%Moat
top 39%Talent
bottom 49%Funding: Raised $2.7B across 2 rounds · 2 rounds over 1 yrs (2.0/yr) · Last round Series B (May 2026)
AI: Classified as an AI company
Innovation: 19 patents (top 47% of patent-holders) · 19 filings since 2022 vs 0 in 2017-21 · Deep-tech classification: Artificial Intelligence
Audience (LinkedIn): 95k LinkedIn followers — 18.4% of this cohort's audience
Funding rounds
- May 2026Series B$2.1B
- Mar 2025Series A$600M
Founders & team
Investors
Thrive Capital, Google Ventures, Alphabet, MGX, Temasek, CapitalG
Tech stack
<Model-Viewer>CloudflareCookiebotGoogle AnalyticsGoogle Hosted LibrariesGsap
#2
Series A · London, England · founded 2023$83Mraised▾
Series A · London, England · founded 2023
Provider of immune cell engagers for treating cancer. It offers a portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells to discriminate between target diseased vs healthy cell for the treatment of solid tumors and other cancer.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 24%Global
top 45%Talent
bottom 49%Funding: Raised $83.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (May 2026)
Global: Investors from 4 countries beyond United Kingdom
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- May 2026Series A$83M
- Seed—
Founders & team
Investors
4Bio Capital, Servier, British Business Bank, Sound Bioventures, Criteria Bio Ventures, Abingworth
#3
Series C · London, England · founded 2015 · 40 employees$106.5Mraised▾
Series C · London, England · founded 2015 · 40 employees
Developer of modular lab automation platforms for biological research workflows. This system integrates hardware and software to orchestrate laboratory processes, including sample handling and instrument management. The platform utilizes node-based design tools and software development kits to enable workflow configuration and simulation. It supports connectivity with external data systems and analytical models to facilitate automated execution of experimental protocols. The hardware components are configurable to accommodate various instruments and laboratory layouts, allowing for the management of multiple concurrent tasks.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 25%Product
top 25%Tech
top 27%Moat
top 31%Innovation
top 32%Fin. health
top 33%Funding: Raised $107M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) · Last round Series C (Jan 2026)
Product: 7 distinct product lines · Company stage: Series C
Tech: 55 technologies across 6/8 capability areas · Cloud: Amazon S3, Amazon Web Services · Devops: Varnish
Audience (LinkedIn): 19k LinkedIn followers — 3.7% of this cohort's audience
Activity (LinkedIn): 1 partnerships (incl. Automata) announced in 12 mo
Funding rounds
- Jan 2026Series C$45M
- Oct 2023Series B$40M
- Feb 2022Series B$50M
- Mar 2019Series A$7.4M
Founders & team
Investors
Dimension, Octopus Ventures, Hummingbird Ventures, Isomer Capital, Possible Ventures, Aldea Ventures
Tech stack
Amazon Web ServicesApple Icloud MailClickceaseCloudflareCloudflare Bot ManagementCookiebot
#4
Series A · London, England · founded 2019 · 7 employees$31Mraised▾
Series A · London, England · founded 2019 · 7 employees
Provider of an AI-based hearing health diagnosis device for medical professionals. The company has developed a portable hearing assessment device for the screening of the hearing abilities of a person. It has another wax removal tool along with the device that removes was from the ear using micro-suction technology. The device can analyze and diagnose the hearing capability of an individual and the data can be shared on other platforms with healthcare professionals.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Growth
top 28%Funding
top 32%Talent
top 33%Tech
top 41%AI
top 45%Product
bottom 48%Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Funding: Raised $31.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Conventional Debt (May 2026)
Talent: 3 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 5k LinkedIn followers
Funding rounds
- May 2026Conventional Debt$2.7M
- Apr 2023Series A$23M
- Feb 2022Seed$8M
Founders & team
Investors
Octopus Ventures, Dara Capital, Rezayat Group, Innovateuk, Myelin, PUBLIC
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCodemirrorCore-JsFancybox
#5
Public · London, England · founded 2006 · 90 employees$222.2Mraised▾
Public · London, England · founded 2006 · 90 employees
Developer of drug delivery technology using tumor activated peptide linkers. This technology attaches peptides to existing therapeutic agents to maintain them in an inactive state while circulating in the bloodstream. The drug remains inactive until it reaches the tumor site, where specific enzymes remove the peptide to release the active medication. This mechanism concentrates the therapeutic effect within the tumor environment.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 21%News
top 35%Moat
top 38%Talent
bottom 49%Tech
bottom 47%Patents
bottom 42%Funding: Raised $222M across 12 rounds · 12 rounds over 15 yrs (0.8/yr) · Last round Post IPO (Oct 2025)
News: 7 BI events in 12 mo (of 34 tracked, 8 types) · -46% YoY · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo
Moat: Editorial + unicorn rating 4/10 · IP moat: 17 patents
Audience (LinkedIn): 9k LinkedIn followers
Funding rounds
- Oct 2025Post IPO$21.5M
- Aug 2025Post IPO$4.4M
- Feb 2024Post IPO$32.5M
- Nov 2022Post IPO$73.1M
Founders & team
Investors
Mrc, IP Group, Swarraton Partners, WG Partners
Tech stack
AddtoanyAddtoany Share ButtonsAosApple Icloud MailCdnjsCloudflare
#6
Series A · London, England · founded 2016 · 16 employees$60.4Mraised▾
Series A · London, England · founded 2016 · 16 employees
Developer of technology for in vitro drug discovery. The company's proprietary technology includes a human-derived biological scaffold for the development of 3D spheroids and tissue engineering systems. The applications of the technology include accelerating in vitro drug discovery and helping patients with end-stage liver disease. The company has also designed BAL to address the unmet need for treatment of liver failure, providing bedside support.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Growth
top 35%Talent
top 38%Funding
top 39%News
top 43%Patents
top 44%Moat
top 47%Growth: Fresh capital in last 24 mo
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $60.4M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) · Last round Series A (Jan 2026)
Audience (LinkedIn): 9k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. GSK) announced in 12 mo
Funding rounds
- Jan 2026Series A$25M
- Jan 2022Series A$54M
- Nov 2018Series A$6.4M
Founders & team
Investors
Dompé, Netherton Investments, UCLB
Tech stack
Apache Http ServerApple Icloud MailCdnjsCloudflareFont AwesomeGsap
#7
Seed · London, England · founded 2019 · 12 employees$65.3Mraised▾
Seed · London, England · founded 2019 · 12 employees
AI-based drug development tools for researchers. The company has developed software for target and drug discovery. The platform leverages human genetics, single-cell omics, and perturbational data for genetic disease management.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 25%Talent
top 28%AI
top 30%Growth
top 35%Moat
top 36%Tech
bottom 43%Funding: Raised $65.3M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) · Last round Seed (Nov 2025)
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
AI: Classified as an AI company · Product described with: ai-based
Audience (LinkedIn): 16k LinkedIn followers — 3.1% of this cohort's audience
Activity (LinkedIn): 1 partnerships · 1 awards (incl. Novatis) announced in 12 mo
Funding rounds
- Nov 2025Seed$36.2M
- Nov 2024Seed$15M
- Jan 2024Seed$40.3M
- May 2022Seed$16M
Founders & team
Investors
DCVC, Magnetic Ventures, OMERS, Khosla Ventures, Firstminute Capital, ARK Investment Management
Tech stack
Apple Icloud MailCloudflareCraft CmsGoogle WorkspaceGsapHsts
#8
Series A · London, England · founded 2016 · 27 employees$16.5Mraised▾
Series A · London, England · founded 2016 · 27 employees
Provider of cloud-based rehabilitation device with a companion app for the patients recovering from medical procedures or hospitalization, particularly those affected by stroke. The company has developed a Bluetooth-enabled personal rehabilitation device with a companion app. The app has developed a series of games in which users squeeze the device and loosen their grip to play. It measures grip strength and hand motion to assess and track the patient's cognitive and physical movements over time through a machine learning algorithm.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Growth
top 21%Funding
top 32%AI
top 45%Talent
bottom 49%Product
bottom 48%Tech
bottom 45%Growth: Headcount 11 → 27 (+145%) across vintages · Fresh capital in last 24 mo
Funding: Raised $16.5M across 6 rounds · 6 rounds over 9 yrs (0.7/yr) · Last round Series A (Mar 2026)
AI: Product described with: machine learning
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Mar 2026Series A$2.7M
- Apr 2022Series A$11M
- Mar 2021Seed$2.2M
- Feb 2019Seed$142.3K
Founders & team
Investors
Oxford Technology, Gov, Triple Point, Imperial College London, IP Group, Parkwalk
Tech stack
AutoptimizeBackbone.JsCloudflareCloudflare Rocket LoaderCookiebotGoogle Analytics
#9
Series B · London, England · founded 2021$17.3Mraised▾
Series B · London, England · founded 2021
Developer of small-molecule therapeutics targeting lysosomal dysfunction in neurodegenerative diseases. The company focuses on developing disease-modifying therapies to restore endo-lysosomal function and reduce neurodegeneration. Their pipeline includes small molecule modulators targeting ATP13A2 and ATP10B lysosomal transporters, both critical for maintaining neuronal health. Initial clinical indications target genetic subsets of Parkinson's disease, with plans to expand into sporadic Parkinson's and other neurodegenerative disorders. The approach aims to address the underlying causes of these diseases rather than just managing symptoms.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 32%Tech
bottom 49%Talent
bottom 49%Global
bottom 48%Market
bottom 25%Funding: Raised $17.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (Mar 2026)
Tech: 13 technologies across 4/8 capability areas · Cloud: Vercel · Security: Hsts
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Mar 2026Series B$17.3M
Founders & team
Investors
SV Health Investors
#10
Acquired · London, England · founded 2016 · 53 employees$18.1Mraised▾
Acquired · London, England · founded 2016 · 53 employees
Leading expert network for healthcare and life sciences. Platform connecting healthcare and life science organizations with subject matter experts. It facilitates primary research by providing access to a network of professionals. The platform offers tools for expert identification, interview scheduling, and automated call analysis. It also provides features for data capture, transcript access, and quote sharing.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 29%Tech
top 30%Growth
top 32%Moat
top 39%Talent
bottom 49%Global
bottom 46%Funding: Raised $18.1M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) · Last round PE (Feb 2026)
Tech: 43 technologies across 5/8 capability areas · Cloud: Amazon Cloudfront, Amazon S3 · Observability: Sentry
Growth: Headcount 39 → 53 (+36%) across vintages · Fresh capital in last 24 mo
Audience (LinkedIn): 7k LinkedIn followers
Funding rounds
- Feb 2026PE$6.7M
- Oct 2021Series B$12M
- Feb 2020Unattributed$4.9M
- Dec 2018Unattributed$1.3M
Founders & team
Investors
ACF Investors, BGF, Nauta Capital, Cambridge Angels, Palatine Private Equity, Martlet Capital
Tech stack
Amazon CloudfrontAmazon S3Amazon Web ServicesBootstrapCdnjsCloudflare
#11
Series A · London, England · founded 2019 · 8 employees$82.7Mraised▾
Series A · London, England · founded 2019 · 8 employees
Developer of antibody therapeutics for treating oncology and neurodegenerative conditions. This organization identifies drug targets by analyzing patient antibody repertoires through deep sequencing and computational analysis. The process focuses on identifying convergent protective antibody responses found in individuals who demonstrate resilience to specific diseases. These findings facilitate the creation of therapeutic candidates intended for clinical application.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 28%Talent
top 28%Moat
top 31%Growth
top 35%Global
bottom 37%Market
bottom 34%Funding: Raised $82.7M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) · Last round Series A (Sep 2025)
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 11k LinkedIn followers — 2.2% of this cohort's audience
Activity (LinkedIn): 1 partnerships · 3 awards (incl. Natural Portfolio) announced in 12 mo
Funding rounds
- Sep 2025Series A$32M
- Dec 2022Grant (prize money)$2.1M
- 2021Grant (prize money)—
- Apr 2021Series A$82.7M
Founders & team
Investors
Innovate UK, SV Health Investors, RA Capital Management, Lightstone Ventures, DCVC, DHVC
Tech stack
DocusignGodaddyGoogle AnalyticsGoogle Font ApiJqueryJquery Migrate
#12
Series A · London, England · founded 2017 · 36 employees$60Mraised▾
Series A · London, England · founded 2017 · 36 employees
Provider of a non-invasive brain-computer interface solution for various industries. It enables users to develop, design, measure, study, record, process, analyze, manage, and control brain data for decision-making. Its offering includes application development, research, neuroimaging, and stimulation technologies. It caters to the health and manufacturing industries.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Growth
top 11%News
top 24%Funding
top 29%Moat
top 42%Partners
top 45%Talent
bottom 49%Growth: Headcount 15 → 36 (+140%) across vintages · Fresh capital in last 24 mo
News: 7 BI events in 12 mo (of 7 tracked, 2 types) · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: Funding, Regulatory
Funding: Raised $60.0M across 1 rounds · 1 rounds over 3 yrs (0.3/yr) · Last round Series A (Oct 2025)
Audience (LinkedIn): 11k LinkedIn followers — 2.1% of this cohort's audience
Funding rounds
- Oct 2025Series A$60M
- 2023Seed—
Founders & team
Investors
Angelini Ventures, LocalGlobe, Octopus Ventures, Crane Venture Partners, Backed, Entrepreneur First
Tech stack
Apple Icloud MailFramer SitesGodaddyGoogle Font ApiGoogle WorkspaceHsts
Funding & investor landscape
$12.1Btotal disclosed funding
271companies funded
688disclosed rounds
5rounds last 90 days
Most active investors
Gov16 rounds
Notable founders
Demis Hassabis
Founder & CEO · Isomorphic Labs
Natalie Mount
CEO · Cytospire Therapeutics
Mostafa ElSayed
Co-Founder & CEO · Automata
Krishan Ramdoo
Founder & CEO · TympaHealth
Stuart Westcott
Finance Director · TympaHealth
Christina Coughlin
CEO · Avacta
Massimo Pinzani
Co-Founder · Engitix
Giuseppe Mazza
Co-Founder & CEO · Engitix
Jake Taylor-King
Co-Founder & Chief Innovation Officer · Relation
Charles Roberts
Co-Founder · Relation
Mike Mace
CTO - Cofounder · GripAble
Joanna Wolak
Co-Founder & CEO · Endlyz
Prism market signals · United Kingdom · country-scoped Prism corpus, 709,332 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN LONDON · Health & Bio
How research on Biotechnology in London is moving
A read on the academic research around Biotechnology in London — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 246 papers.
London's Imperial College, UCL, and King's College drive predominantly optimistic RNA, CRISPR, and malaria biotechnology research, with recent output surging fourfold amid cautiously balanced breakthrough-to-concern sentiment.
246 papers · stance +0.42 · 40% breakthrough · 21% concern
top institutions
- Imperial College London70
- University College London67
- King\'s College London41
- London School of Hygiene & Tropical Medicine28
- Queen Mary University of London22
leading researchers
Beatriz Sanchez-Pintado · Emily R. Eden · Farah Olivia Rezek · Julio C. Corral-Serrano · Nancy Aychoua · Carina Graham
prism intelligence · tone & topics
89% positive · 6% critical tone
HealthMedical ResearchPharmaceuticalsGeneticsBiologyClinical Trials
▲
Breakthroughs81 · 33%
▼ 36%→33% share
▼0.9× share momentum0 median citations79% since 2021mostly empirical
Gene research newly dominates Breakthroughs with 8 papers, while Antibody and Chromatin topics each quadrupled.
rising sub-themes (early→recent)
- Antibody1→4
- Chromatin1→4
Newly emergingGene 0→8 · Mutation 0→5 · Oligonucleotide 0→5
Landmark Biomedical photoacoustic imaging · 2,130 cites
◆
Advancements77 · 31%
▲ 19%→34% share
▲1.8× share momentum0 median citations86% since 2021mostly empirical
Advancements field-share nearly doubled (19%→34%), led by brand-new Gene (8) and Antimicrobial (6) entries.
rising sub-themes (early→recent)
- Messenger RNA1→3
Newly emergingGene 0→8 · Antimicrobial 0→6 · Cell culture 0→4
Landmark Characterization of a Novel, Water-Soluble Hydrogen Sulfide–Releasing Molecule (GYY4137) · 824 cites
▼
Concerns42 · 17%
▼ 23%→15% share
▼0.7× share momentum0 median citations67% since 2021mostly reviews
Concerns field-share cooling (23%→15%), yet Antibiotic resistance tripled and Drug resistance newly emerged with 3 papers.
rising sub-themes (early→recent)
- Antibiotic resistance1→3
Newly emergingAntimicrobial 0→3 · Drug resistance 0→3 · Disease 0→3
Landmark Top 10 plant pathogenic bacteria in molecular plant pathology · 2,329 cites
Common questions
How many Life Sciences companies are there in London, United Kingdom?
Radar tracks 632 indexable Life Sciences companies headquartered in London, United Kingdom that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in London, United Kingdom?
The Life Sciences companies in London, United Kingdom on this list have raised a combined $12.1B in disclosed equity funding across 271 funded companies.
Which is the highest-funded Life Sciences company in London, United Kingdom?
Isomorphic Labs is the highest-funded Life Sciences company in London, United Kingdom, with $2.7B in disclosed equity funding.
How many Life Sciences companies in London, United Kingdom are funded?
271 of the 632 Life Sciences companies in London, United Kingdom on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in London, United Kingdom?
1 Life Sciences company in London, United Kingdom on this list is valued at $1B or more.
Who are the top investors in London, United Kingdom Life Sciences companies?
The most active investors in London, United Kingdom Life Sciences companies on this list include Europa, Entrepreneur First, Gov, P4, Ukri.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.